EU-OPENSCREEN officially launched as European Research Infrastructure
Consortium to drive development of new active ingredients
In April 2018 the European Commission awarded the prestigious status of a European Research Infrastructure Consortium (ERIC) to the EU-OPENSCREEN consortium. The ERIC-insignia of excellence was presented on September 25 during a ceremonial act hosted by Campus Berlin-Buch.
This consortium was advanced and guided over the past 10 years by the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin together with the Max-Delbrück-Center for Molecular Medicine in Berlin (MDC) and the Helmholtz-Centre for Infection Research (HZI) in Braunschweig. All three institutes are active partners in the Helmholtz Drug Research Initiative. In addition to FMP, MDC and HZI, the Fraunhofer-Institute for Molecular Biology and Applied Ecology (IME) joins as the fourth partner in Germany.
The consortium coordinates the infrastructures of 20 Research institutes in seven European countries for the advancement of the discovery of new drugs. EU-OPENSCREEN ERIC (www.eu-openscreen.eu) operates its central office in Germany on the Research Campus Berlin-Buch. Next to Germany, the group of founding member countries includes Norway, Czech Republic, Latvia, Finland, Poland and Spain. Denmark joined as observer, but becomes full member in 2019. Several other countries prepare for membership.
Central activities of EU-OPESCREEN-ERIC are funded by the partner countries, and in Germany by the Ministry for Education and Research (BMBF) with ca. 23 Million Euros. Future additional financial support could be secured by four successful Horizon2020 grant applications. Among these is a project with 33 partners, funded with five million Euros, and is coordinated by EU-OPESCREEN-ERIC during the coming four years.